Literature DB >> 25661758

Prevalence and treatment of "balloon-uncrossable" coronary chronic total occlusions.

Siddharth M Patel1, Nagendra R Pokala, Rohan V Menon, Anna P Kotsia, Vijay Raja, George Christopoulos, Tesfaldet T Michael, Bavana V Rangan, Daniel Sherbet, Vishal G Patel, Shuaib A Abdullah, Jeffrey Hastings, Jerrold M Grodin, Subhash Banerjee, Emmanouil S Brilakis.   

Abstract

BACKGROUND: The frequency and outcomes of "balloon-uncrossable" coronary chronic total occlusions (CTOs) have received limited study.
METHODS: We retrospectively examined 373 consecutive CTO percutaneous coronary interventions (PCIs) performed at our institution between 2005 and 2013 to determine the frequency and treatment of balloon-uncrossable CTOs.
RESULTS: Mean age was 63.7 ± 8.3 years and 98.9% of the patients were men. Twenty-four patients (6.4%, 95% confidence intervals 4.2% to 9.4%) were found to have a balloon-uncrossable CTO. Compared to the other CTO PCI patients, those with balloon-uncrossable CTOs had similar clinical and angiographic characteristics. Successful crossing of the balloon-uncrossable CTO was achieved in 22 of 24 patients (91.7%) using a variety of techniques, such as successive balloon inflations (43.5%), microcatheter advancement (21.7%), laser (8.7%), techniques that increase guide catheter support (13.0%), and subintimal lesion crossing (13.0%). Patients with balloon-uncrossable CTOs had longer procedure time (184.5 ± 77.9 vs 134.0 ± 69.0 min, P<.01), fluoroscopy time (55.2 ± 24.9 vs 37.9 ± 20.8 min, P<.01), and received high contrast volume (404.4 ± 137.9 vs 351.7 ± 138.5 mL, P=.08), but had similar incidence of major complications (8.3% vs 3.2%, P=.25) as compared with patients who did not have balloon-uncrossable CTOs.
CONCLUSION: Balloon-uncrossable CTOs are encountered in 6.4% of contemporary CTO PCIs and can be successfully treated in most patients using a variety of techniques.

Entities:  

Mesh:

Year:  2015        PMID: 25661758

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  6 in total

Review 1.  Approach to CTO Intervention: Overview of Techniques.

Authors:  Aris Karatasakis; Barbara Anna Danek; Dimitri Karmpaliotis; Khaldoon Alaswad; Minh Vo; Mauro Carlino; Mitul P Patel; Stéphane Rinfret; Emmanouil S Brilakis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-01

2.  Lesion characteristics and procedural outcomes of re-attempted percutaneous coronary interventions for chronic total occlusion.

Authors:  Masaki Tanabe; Kenji Kodama; Kohei Asada; Takeo Kunitomo
Journal:  Heart Vessels       Date:  2017-12-09       Impact factor: 2.037

3.  Prevalence, Presentation and Treatment of 'Balloon Undilatable' Chronic Total Occlusions: Insights from a Multicenter US Registry.

Authors:  Peter Tajti; Dimitri Karmpaliotis; Khaldoon Alaswad; Catalin Toma; James W Choi; Farouc A Jaffer; Anthony H Doing; Mitul Patel; Ehtisham Mahmud; Barry Uretsky; Aris Karatasakis; Judit Karacsonyi; Barbara A Danek; Bavana V Rangan; Subhash Banerjee; Imre Ungi; Emmanouil S Brilakis
Journal:  Catheter Cardiovasc Interv       Date:  2018-01-23       Impact factor: 2.692

Review 4.  Chronic Total Occlusion Interventions: Update on Current Tips and Tricks.

Authors:  Peter Tajti; Iosif Xenogiannis; Dimitris Karmpaliotis; Khaldoon Alaswad; Farouc A Jaffer; M Nicholas Burke; Imre Ungi; Emmanouil S Brilakis
Journal:  Curr Cardiol Rep       Date:  2018-10-22       Impact factor: 2.931

Review 5.  Interventional Management of "Balloon-Uncrossable" Coronary Chronic Total Occlusion: Is There Any Way Out?

Authors:  Debabrata Dash
Journal:  Korean Circ J       Date:  2018-04       Impact factor: 3.243

6.  Novel predictors of outcome after coronary angioplasty with rotational atherectomy. Not only low ejection fraction and clinical parameters matter.

Authors:  Piotr Kübler; Wojciech Zimoch; Michał Kosowski; Brunon Tomasiewicz; Oscar Rakotoarison; Artur Telichowski; Krzysztof Reczuch
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-03-22       Impact factor: 1.426

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.